报价延迟最少15分钟:2025/08/26 07:44 EDT
盘前时段
|
||||
|
10.89 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
10.89
|
|
|
| 价值评估 |
|
盈利(现时/预测)
0.09/0.79
|
|
企业价值
389.92M
|
| 资产负债 |
|
每股账面净值
3.00
|
| 现金流量 |
|
现金流量率
0.01
|
| 损益表 |
|
收益
37.21M
|
|
每股收益
0.08
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/08/26 07:44 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS,is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe. |
